For your adult patients with relapsed or
refractory multiple myeloma in combination
with
carfilzomib and dexamethasone (Kd) or pomalidomide and dexamethasone (Pd)
THIS IS WHAT EFFICACY
LOOKS LIKE WITH sarclisa
Choose sarclisa + Kd or Pd as early as first relapse
for improved PFS vs Kd or Pd alone1
Consider sarclisa + Kd
at first relapse1
Explore Patient Types
See the phase 3 ikema trial
Explore sarclisa + KdSee the phase 3
icaria-MM trial
Explore sarclisa + Pd
ikema mPFS: Not yet reached (NR) with sarclisa + Kd (n=179) vs 20.27 months with Kd alone (n=123), HR=0.548 (95% CI: 0.37, 0.82; P=0.0032).1
icaria-MM mPFS: 11.53 months with sarclisa + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010).1
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
for Multiple Myeloma recommend isatuximab-irfc (sarclisa) as a Category 1 Preferred option for early relapses2*
- In combination with pomalidomide and dexamethasone
- In combination with carfilzomib and dexamethasone
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
*1-3 prior therapies.2
mPFS=median progression-free survival; NCCN=National
Comprehensive Cancer Network; PFS=progression-free survival.